Could a shorter drug course be just as effective for elderly AML patients?
NCT ID NCT07407660
First seen Feb 20, 2026 · Last updated May 16, 2026 · Updated 9 times
Summary
This study looks at whether older or frail patients with acute myeloid leukemia (AML) can safely take a shorter course of the drug venetoclax, based on their bone marrow results on Day 14, instead of the standard longer course. About 250 participants will be randomly assigned to either the shortened or standard treatment, both combined with azacitidine. The goal is to see if the shorter approach works just as well while possibly reducing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.